ALK (L1152R)
Sign in to save this workspaceALK · Variant type: point · HGVS: p.L1152R
Drug response on this variant
| # | Drug | Inhibition on variant | Residual | KISS |
|---|---|---|---|---|
| 1 | Brigatinib | 99.8% | 0.2% | 82.96 |
| 2 | Gilteritinib | 99.7% | 0.3% | 88.97 |
| 3 | Entrectinib | 99.4% | 0.6% | 93.69 |
| 4 | Repotrectinib | 99.3% | 0.7% | 84.21 |
| 5 | Lorlatinib | 98.4% | 1.6% | 97.24 |
| 6 | Alectinib | 98.2% | 1.8% | 95.49 |
| 7 | Ceritinib | 98.1% | 1.9% | 95.44 |
| 8 | Sunitinib | 97.5% | 2.5% | 91.73 |
| 9 | Crizotinib | 97.2% | 2.8% | 91.39 |
| 10 | Pralsetinib | 95.2% | 4.8% | 93.43 |
| 11 | Ruxolitinib | 92.7% | 7.3% | 98.25 |
| 12 | Pacritinib | 92.6% | 7.4% | 88.64 |
| 13 | Alpelisib | 92.1% | 7.9% | 97.22 |
| 14 | Baricitinib | 90.8% | 9.2% | 97.99 |
| 15 | Nintedanib | 90.1% | 9.9% | 90.23 |
| 16 | Osimertinib | 90.0% | 10.0% | 97.24 |
| 17 | Lazertinib | 74.8% | 25.2% | 97.47 |
| 18 | Bosutinib | 60.6% | 39.4% | 87.22 |
| 19 | Fedratinib | 59.0% | 41.0% | 96.21 |
| 20 | Tenalisib | 51.5% | 48.5% | 97.98 |
| 21 | Upadacitinib | 44.2% | 55.8% | 97.98 |
| 22 | Defactinib | 42.3% | 57.7% | 92.68 |
| 23 | Fostamatinib | 40.0% | 60.0% | 96.74 |
| 24 | Pazopanib | 38.6% | 61.4% | 97.49 |
| 25 | Tepotinib | 36.7% | 63.3% | 99.75 |
Wild-type vs variant — drug response delta
Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).
| Drug | Variant inh | WT inh | Δ (variant − WT) |
|---|---|---|---|
| Brigatinib | 99.8% | 99.2% | +0.6% |
| Gilteritinib | 99.7% | 99.5% | +0.2% |
| Entrectinib | 99.4% | 98.8% | +0.6% |
| Repotrectinib | 99.3% | 99.4% | -0.0% |
| Lorlatinib | 98.4% | 97.2% | +1.2% |
| Alectinib | 98.2% | 98.6% | -0.3% |
| Ceritinib | 98.1% | 98.3% | -0.1% |
| Sunitinib | 97.5% | 87.7% | +9.8% |
| Crizotinib | 97.2% | 97.7% | -0.5% |
| Pralsetinib | 95.2% | 82.6% | +12.7% |
| Ruxolitinib | 92.7% | 52.1% | +40.7% |
| Pacritinib | 92.6% | 55.3% | +37.3% |
| Alpelisib | 92.1% | 80.7% | +11.4% |
| Baricitinib | 90.8% | 46.4% | +44.5% |
| Nintedanib | 90.1% | 84.9% | +5.3% |
| Osimertinib | 90.0% | 80.5% | +9.5% |
| Lazertinib | 74.8% | 46.3% | +28.5% |
| Bosutinib | 60.6% | 75.1% | -14.5% |
| Fedratinib | 59.0% | — | — |
| Tenalisib | 51.5% | 45.2% | +6.3% |
| Upadacitinib | 44.2% | — | — |
| Defactinib | 42.3% | — | — |
| Fostamatinib | 40.0% | — | — |
| Pazopanib | 38.6% | — | — |
| Tepotinib | 36.7% | — | — |
Cancer associations
| Cancer | Organ | Source |
|---|---|---|
| carcinoma_lung | Lung | ref |
Annotations
Sign in to read and post annotations.
Loading…
Served from saifudeen2026@1.0.0 · API 0.1.0 · 19.5ms